Business Context and Reporting Period
Company: Champions Biotechnology, Inc. (also referred to as Champions Oncology, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: July 31, 2009
Business Overview: A biotechnology company developing advanced preclinical platforms (Biomerk Tumorgrafts) and predictive tumor-specific data to enhance oncology drug development. The company also provides personalized oncology services to physicians.
Key Financial Metrics
| Metric | Three Months Ended July 31, 2009 | Three Months Ended July 31, 2008 |
|---|---|---|
| Total Operating Revenue | $962,000 | $673,000 |
| Net Loss | $(1,003,000) | $(131,000) |
| Net Loss Per Share (Basic & Diluted) | $(0.03) | $(0.00) |
| Cash and Cash Equivalents (End of Period) | $1,530,000 | $3,495,000 |
| Working Capital | $39,000 | $1,166,000 (April 30, 2009) |
| Net Cash Used in Operating Activities | $(1,018,000) | $(207,000) |
Revenue Breakdown (Q1 2009): Personalized oncology services ($899,000); Preclinical eValuation services ($63,000).
Expense Breakdown (Q1 2009): Cost of personalized oncology services ($634,000); Research and development ($496,000); General and administrative ($806,000).
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased by 43% ($289,000) compared to the prior year quarter, driven primarily by a 46% increase in personalized oncology services.
- Expense Surge: Total operating expenses increased by 139% ($1,145,000). Cost of personalized oncology services rose 181% due to higher-cost tumorgraft studies. General and administrative expenses increased 141% due to infrastructure expansion in the U.S., Israel, and U.K.
- Widening Loss: Net loss increased significantly from $131,000 to $1,003,000 as expense growth outpaced revenue growth.
- Liquidity Decline: Working capital decreased from $1,166,000 (April 30, 2009) to $39,000 (July 31, 2009). Cash decreased by $198,000 during the quarter.
Outlook, Risks, and Management Commentary
- Going Concern Uncertainty: Management states the company has experienced recurring losses and will require additional capital to fund near-term operating losses. There is no assurance that fundraising efforts (including a potential private placement) will succeed.
- Capital Raising: The Board authorized management in June 2009 to begin raising additional capital. Failure to secure funding could materially impact operations.
- Related Party Transaction: The company entered a stock repurchase agreement with a Board member, obligating the company to purchase up to $400,000 of stock over two years. As of July 31, 2009, $250,000 remained to be paid under this agreement.
- Internal Controls: Management determined that disclosure controls and procedures were not effective as of the filing date due to material weaknesses previously identified.
- Strategic Focus: The company is developing a soluble form of its lead drug candidate, SG410, and intends to sell, partner, or license it upon promising preclinical results.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $1.53 million cash balance against the $1.02 million quarterly operating cash burn rate.
- Fundraising Status: Confirm the status of the private placement or other capital raising efforts mentioned in the "Going Concern" note.
- Stock Repurchase Obligation: Monitor the $250,000 remaining liability under the related party stock repurchase agreement and its impact on future cash flow.
- Internal Controls: Review progress on remediation of the material weaknesses in internal controls over financial reporting.
- Revenue Quality: Assess the sustainability of the 46% revenue growth in personalized oncology services given the 181% increase in associated costs.